Theravance Biopharma, Inc. $TBPH Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 51.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,535 shares of the biopharmaceutical company's stock after selling 23,515 shares during the quarter. Invesco Ltd.'s holdings in Theravance Biopharma were worth $201,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Theravance Biopharma by 1,201.8% in the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares during the last quarter. R Squared Ltd increased its position in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of Theravance Biopharma in the 4th quarter worth about $119,000. Tabor Asset Management LP bought a new stake in shares of Theravance Biopharma in the 1st quarter worth about $135,000. Finally, XTX Topco Ltd increased its position in shares of Theravance Biopharma by 20.8% in the 1st quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company's stock worth $176,000 after purchasing an additional 3,403 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president directly owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.90% of the company's stock.

Analyst Ratings Changes

TBPH has been the subject of several research analyst reports. BTIG Research boosted their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. Finally, B. Riley initiated coverage on shares of Theravance Biopharma in a research report on Friday. They set a "buy" rating and a $28.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Strong Buy" and a consensus target price of $23.00.

Theravance Biopharma Trading Up 4.4%

Theravance Biopharma stock traded up $0.60 during midday trading on Friday, reaching $14.30. 848,891 shares of the stock traded hands, compared to its average volume of 527,745. The firm has a fifty day moving average price of $12.39 and a two-hundred day moving average price of $10.60. The firm has a market cap of $720.15 million, a price-to-earnings ratio of 59.58 and a beta of 0.05. Theravance Biopharma, Inc. has a fifty-two week low of $7.88 and a fifty-two week high of $14.55.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.